Prana Biotechnology Ltd. (Nasdaq: PRAN) reported disappointing results from a Phase 2 Imagine trial of its Alzheimer's disease treatment PBT2 sending the stock price plummeting $6.99 to $2.87.
Prana Trial Results Disappoint
March 31, 2014 at 14:24 PM EDT
